Showing 7 posts of 7 posts found.


China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019
Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …

Eisai image

Eisai earns FDA nod for Fycompa

June 22, 2015
Sales and Marketing Eisai, FDA, Fycompa

The FDA has expanded the patient groups for whom Eisai’s epilepsy drug Fycompa is available to include people who have …


Eisai epilepsy drug sees EMA nod

May 27, 2015
Research and Development, Sales and Marketing Eisai, Fycompa, ema. epilepsy

Eisai’s UK subsidiary has received a positive opinion from the European Medicines Agency for using Fycompa for the adjunctive treatment …

Eisai image

Eisai: Fycompa decision ‘deeply regrettable’

November 11, 2014
Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel

Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …

Eisai image

SMC first to give Fycompa thumbs-up

December 12, 2012
Sales and Marketing Eisai, Fycompa, SMC, Scotland, epilepsy

The Scottish Medicines Consortium (SMC) has approved Eisai’s first-in-class epilepsy drug Fycompa for use in the NHS in Scotland – …

Eisai image

Eisai opens Fycompa UK manufacturing line

September 25, 2012
Manufacturing and Production, Sales and Marketing Eisai, Fycompa

Eisai has opened a new solid dose production line for epilepsy drug Fycompa at its UK base in Hatfield, Hertfordshire. …

Halaven image

UK at centre of Eisai plans

September 18, 2012
Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven

Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …

Latest content